India · Delayed Price · Currency is INR Eris Lifesciences Earnings Call Transcripts
Fiscal Year 2026
-
Domestic and consolidated revenues grew 11% and 8% respectively, with strong insulin and derma segment performance and rapid semaglutide uptake. Regulatory delays and supply chain issues impacted some launches and international shipments, but margin guidance and capital efficiency are expected to improve.
-
Q3 and nine-month results showed double-digit revenue and profit growth, margin expansion, and strong market share gains in insulins and cardiac care. Strategic launches, discontinuation of non-core brands, and robust CDMO order book position the company for continued growth and margin improvement.
-
Q2 saw 10% domestic revenue growth and 11% EBITDA growth, with Biocon margins rising to 32%. International business expanded, and the European CDMO order book reached INR 700-800 crore. CapEx is front-loaded, with net debt-to-EBITDA expected below 1.5x by Dec 2026.
-
DBF segment delivered 11% revenue growth and 37% EBITDA margin, while consolidated profit after tax rose 41% year-on-year. Insulin and GLP-1 capacity expansions are on track, and the international business is pivoting to higher-margin EU markets with confirmed CDMO contracts.
Fiscal Year 2025
-
Q4 revenue grew 28% year-on-year to INR 705 crores, with EBITDA up 70% and strong margin expansion. FY 2025 saw robust growth in DBF and Swiss Parenterals, improved ROCE, and significant debt reduction, with FY 2026 guidance projecting continued double-digit growth and margin improvement.
-
Q3 and nine-month results show strong 12% organic growth, 50% consolidated revenue growth, and significant EBITDA margin expansion. Debt reduction is ahead of schedule, with EPS growth expected to exceed 50% in FY26, driven by margin gains, new launches, and lower tax rates.
-
Q2 revenue grew 47% year-over-year to INR 741 crores, with EBITDA up 46% and margins stable. Integration of acquisitions and manufacturing improvements drove margin expansion and cost synergies. Guidance for FY 2025 is reaffirmed, with new product launches and strategic investments set to support future growth.
-
Q1 FY25 saw 54% revenue growth and 47% EBITDA growth, driven by strong integration of Biocon acquisitions and margin expansion. FY25 guidance targets INR 3,000+ crore revenue and 35% EBITDA margin, with significant investments in biotech and debt reduction underway.